Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 1

Status

Active not recruiting 5Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 42Thoracic 20Genitourinary 6Other solid neoplasm 5Head & Neck 4Gynecologic 3Breast 2Tumor-Agnostic 1Other hematologic neoplasm 1Endocrine 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 4Urothelial Cancer 1Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
tremelimumab × Genitourinary × 1 year × Clear all
NCT04960709 2026-06-04

VOLGA

AstraZeneca

Phase 3 Active not recruiting
712 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03682068 2026-05-28

NILE

AstraZeneca

Phase 3 Active not recruiting
1,246 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
13 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca

Phase 3 Active not recruiting
1,126 enrolled 52 charts
Genitourinary

Urothelial Cancer

NCT03317158 2026-04-15

ADAPT-BLADDER

Hoosier Cancer Research Network

Phase 1/2 Recruiting
55 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡